A pharmaceutical container of the present invention is a pharmaceutical container including at least a container and a coating layer, and is characterized that the coating layer is coated on at least an inner surface of the container and the coating layer contains a silicone-based resin.

A flat glass is provided that exhibits high transmittance to electromagnetic radiation in a range of wavelengths from 200 nm to 1500 nm. The transmittance for the flat glass having a thickness of 1 mm is 20% or more at a wavelength of 254 nm, 82% or more at a wavelength of 300 nm, 90% or more at a wavelength of 350 nm, 92% or more at a wavelength of 546 nm, 92.5% or more at a wavelength of 1400 nm, 91.5% or more in a wavelength range from 380 nm to 780 nm, and 92.5% or more in a wavelength range from 780 nm to 1500 nm.

The glass for covering a semiconductor element contains: in mol %, as a glass composition, SiO.sub.2: 20% to 36%, ZnO: 8% to 40%, B.sub.2O.sub.3: 10% to 24%, Al.sub.2O.sub.3: 10% to 20%, and MgO+CaO: 8% to 22%, in which SiO.sub.2/ZnO is 0.6 or more and less than 3.3 in terms of a molar ratio, and a lead component is substantially not contained.

The glass for covering a semiconductor element contains: in mol %, as a glass composition, SiO.sub.2: 20% to 36%, ZnO: 8% to 40%, B.sub.2O.sub.3: 10% to 24%, Al.sub.2O.sub.3: 10% to 20%, and MgO+CaO: 8% to 22%, in which SiO.sub.2/ZnO is 0.6 or more and less than 3.3 in terms of a molar ratio, and a lead component is substantially not contained.

Provided is a method for producing a porous glass member whereby excellent productivity can be achieved because of a high etching rate during acidic treatment and a porous glass member having excellent alkali resistance can be obtained. A method for producing a porous glass member includes the steps of: subjecting a glass base material containing, in terms of % by mole, 40 to 80% SiO.sub.2, over 0 to 40% B.sub.2O.sub.3, 0 to 20% Li.sub.2O, 0 to 20% Na.sub.aO, 0 to 20% K.sub.2O, over 0 to 10% TiO.sub.2, over 0 to 20% ZrO.sub.2, 0 to 10% Al.sub.2O.sub.3, and 0 to 20% RO (where R represents at least one selected from among Mg, Ca, Sr, and Ba) and having a molar ratio of Li.sub.2O/Na.sub.2O of 0 to 0.16 to thermal treatment to separate the glass base material into two phases; and removing one of the two phases with an acid.

Provided is a method for producing a porous glass member whereby excellent productivity can be achieved because of a high etching rate during acidic treatment and a porous glass member having excellent alkali resistance can be obtained. A method for producing a porous glass member includes the steps of: subjecting a glass base material containing, in terms of % by mole, 40 to 80% SiO.sub.2, over 0 to 40% B.sub.2O.sub.3, 0 to 20% Li.sub.2O, 0 to 20% Na.sub.aO, 0 to 20% K.sub.2O, over 0 to 10% TiO.sub.2, over 0 to 20% ZrO.sub.2, 0 to 10% Al.sub.2O.sub.3, and 0 to 20% RO (where R represents at least one selected from among Mg, Ca, Sr, and Ba) and having a molar ratio of Li.sub.2O/Na.sub.2O of 0 to 0.16 to thermal treatment to separate the glass base material into two phases; and removing one of the two phases with an acid.

A plate-like chemically strengthened glass having a compression stress layer on the surface of the glass, wherein the compressive stress value (CS.sub.0) at the glass surface of is 500 MPa or more, the plate thickness (t) is 400 μm or more, the compressive stress depth of layer (DOL) is (t×0.15) μm or more, the compressive stress values (CS.sub.1) and (CS.sub.2) when the depth from the glass surface is ¼ and ½, respectively, are 50 MPa or more, m.sub.1 expressed by {m.sub.1=(CS.sub.1−CS.sub.2/(DOL/4−DOL/2)} is −1.5 MPa/μm or more, m.sub.2 expressed by {m.sub.2=(CS.sub.2/(DOL/2−DOL)} is 0 MPa/μm or less, and m.sub.2 is less than m.sub.1.

A plate-like chemically strengthened glass having a compression stress layer on the surface of the glass, wherein the compressive stress value (CS.sub.0) at the glass surface of is 500 MPa or more, the plate thickness (t) is 400 μm or more, the compressive stress depth of layer (DOL) is (t×0.15) μm or more, the compressive stress values (CS.sub.1) and (CS.sub.2) when the depth from the glass surface is ¼ and ½, respectively, are 50 MPa or more, m.sub.1 expressed by {m.sub.1=(CS.sub.1−CS.sub.2/(DOL/4−DOL/2)} is −1.5 MPa/μm or more, m.sub.2 expressed by {m.sub.2=(CS.sub.2/(DOL/2−DOL)} is 0 MPa/μm or less, and m.sub.2 is less than m.sub.1.

The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, PEDIARIX® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine), HAVRIX® (Hepatitis A Vaccine), ENGERIX-B® (Hepatitis B Vaccine (Recombinant)), TWINRIX® (Hepatitis A & Hepatitis B (Recombinant) Vaccine), EPERZAN® (albiglutide), MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (astuprotimut-R), GSK2402968 (drisapersen), and HZ/su (herpes zoster vaccine).

The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, PEDIARIX® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine), HAVRIX® (Hepatitis A Vaccine), ENGERIX-B® (Hepatitis B Vaccine (Recombinant)), TWINRIX® (Hepatitis A & Hepatitis B (Recombinant) Vaccine), EPERZAN® (albiglutide), MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (astuprotimut-R), GSK2402968 (drisapersen), and HZ/su (herpes zoster vaccine).